Muscle metastasis of low-grade endometrial carcinoma seven years after diagnosis: A case report

Background: Early-stage low-grade endometrial carcinoma has an excellent prognosis. In few cases local relapse and/or distant metastases can occur. We report the muscle as an unusual site of metastasis. Case: A 69-year-old woman underwent surgery for FIGO Stage IA, grade 1 endometrioid adenocarcinoma of the endometrium. After four years she had local relapse without response to chemoradiation, requiring pelvic exanteration. Three years later she was diagnosed with a deltoid muscle metastasis confirmed histologically and bone metastases. After failing hormone therapy, chemotherapy was administered. She died eight months after diagnosis of the bone and muscle metastases. Conclusion: Low-risk endometrial carcinoma can behave like a high-risk group. Furthermore, this report describes, to our knowledge, the first case of endometrial carcinoma muscle metastasis.

Endometrial cancer; Early stage; Muscle metastasis; Bone metastases.

[1] Jemal A., Murray T., Ward E., Samuels A., Tirwari R.C., Ghafoor A. et al.: “Cancer statistics”. CA Cancer J. Clin., 2005, 55, 10.

[2] Abdul-Karim F.W., Kida M., Wentz W.B. et al.: “Bone metastases from gynaecologic carcinomas: clinicopathologic study”. Gynecol. Oncol., 1990, 39, 108.

[3] Aalders J.G., Abeler V., Kolstad P.: “Recurrent adenocarcinoma of the endometrium: a clinical and histopathological study of 379 patients”. Gynecol. Oncol., 1984, 17, 85.

[4] Reddoch J.M., Burke T.W., Morris M., Tornos C., Levenback C.,Gershenson D.M.: “Surveillance for recurrent endometrial carcinoma: development of a follow-up scheme”. Gynecol. Oncol., 1995, 59, 221.

[5] Yoonessi M., Anderson D.G., Morley G.W.: “Endometrial carci-noma: causes of death and sites of treatment failure”. Cancer, 1979, 43, 1944.

[6] Morris M., Alvarez R., Kinney W., Wilson T.: “Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration”. Gynecol. Oncol., 1996, 60, 288.

[7] Barakat R., Goldman N., Patel D., Venkatraman E., Curtin J.: “Pelvic exenteration for recurrent endometrial cancer”. Gynecol. Oncol., 1999, 75, 99.

[8] Sahinler I., Erkal H., Akyazici E., Atkovar G., Okkan S.: “Endometrial carcinoma and an unusual presentation of bone metastasis: a case report”. Gynecol. Oncol., 2001, 82, 216.

[9] Decruze S.B., Green J.A.: “Hormone therapy in advanced and recurrent endometrial cancer: a systematic review”. Int. J. Gynecol. Cancer, 2007, 17, 964.

[10] Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R. et al.: “Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: A Gynecologic Oncology Group Study”. J. Clin. Oncol., 2004, 22, 2159.

[11] Hoskins P.J., Swenerton K.D., Pike J.A., Wong F., Lim P., Acquino-Parsons C. et al.: “Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: A phase II study”. J. Clin. Oncol., 2001, 19, 4048.

[12] Oza A.M., Elit L., Biagi J., Chapman M., Tsao M., Hedley D. et al.: “Molecular correlates associated with a phase II study of tem-sirolimus (CCI779) in patients with metastatic of recurrent endometrial cancer - NCIC IND 160”. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I, 2006, 24, 3003.

[13] Colombo N., McMeekin S., Schwartz P., Kostka J., Sessa C., Gehrig P. et al.: “Phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer”. J. Clin. Oncol. ASCO Annual Meeting Proceedings Part I, 2007, 25, 5516.